The Canadian Hemophilia Society (CHS) recently announced a Call for Applications for its research programs for the 2021/2022 grant period.  A summary of each program is provided below.   


1)     Dream of a Cure Research Program 



  • To support research focused on improving the health and quality of life of all people with inherited bleeding disorders and finding a cure 
  • To provide basic scientific research grants in fields relevant to hemophilia A and B, von Willebrand disease, rare factor deficiencies, and platelet function disorders and (and platelet pathophysiology) ultimately, at finding a cure 

Up to $75,000 per year and per project for a maximum of $150,000 

Up to 3 years 

For further information and application form, please visit the following link: 

2)     CHS/PFIZER Care Until Cure Research Program 


  • To allow Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation 
  • To support clinical research in fields relevant to improving the quality of life of persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder. 

 Researchers are encouraged to submit proposals within specific areas of interest.  The 2021-2022 Areas of Interest include and are not limited to: 


Hemophilia A or B 

  1. Epidemiology / burden of disease / outcome research 
  2.  “Real World” observational data/patient reported outcomes to describe the current standard of care or burden of disease 
  3. Tailoring/Personalized Hemophilia Treatment (e.g., prophylaxis regimen, pharmacokinetics, adherence and other factors) 
  4.  The role of extravascular Factor IX in hemostasis 
  5. Mild Hemophilia: natural history, clinical outcomes, patient reported outcomes, healthcare utilization and cost, quality of life and joint surveillance 
  6. New considerations in the management of special populations: adolescents, carriers or ageing populations  
  7. “Real World” Observational Data on Factor Utilization and Cost-effectiveness 


Clinical monitoring of hemophilia treatment  

  1. Inhibitors, Inhibitor Management (eg, Immune tolerance), and Immunogenicity 
  2. Product Switching Experience: clinical and patient reported outcomes, rationale for switch, and clinical monitoring 
  3. Joint Outcomes and the Role of Point-of-care Joint Ultrasonography in the Management of Hemophilia 


Basic Science of Gene Therapy for Hemophilia 

  1. Basic science, tropism, transduction efficiency & tolerability of adeno-associated virus (AAV) 
  2. Epidemiology of AAV seropositivity 
  3. AAV antibody Titer assessment, reduction, tolerance 
  4. Role of immunosuppression in managing transaminitis 


Basic Science of TFPI& Anti-TFPI Monoclonal Antibodies 

  1. Regulation of Coagulation 
  2. Basic biology of TFPI interactions with Protein C, ATIII, & Protein S 
  3. Cross talk among regulators interacting with TFPI (e.g. Protein S being a co-factor for both Protein C and TFPI) 
  4. Role of different TFPI pools in regulation of coagulation 
  5. Pharmacology resulting from concomitant treatments (especially antifibrinolytics) added to anti-TFPI 


Antifibrinolytic Therapy 


For further information and application form, please visit the following link: 



Not eligible 



Up to $75,000 per year and per project for a maximum of $150,000 



Up to 3 years 


Application due at ORS for full review  Monday, November 2, 2020 
Application and fully signed ORS Checklist due at ORS for required review  by 9:00 am Thursday, November 12, 2020 
Application due at agency  Monday, November 16, 2020 



Please contact your Faculty Research Officer for information on their internal deadlines. 


ORS is accepting electronic applications – the process is outlined here: